It is possible that the administration of TLR7 agonist needs to be synchronous with the RT-induced changes in the tumor microenvironment such as tumor cell death and release of TAAs and DAMPs to augment successful CD8+ priming. This evidence concerns the gene TLR7 and neoplasm.